Ignite Creation Date:
2024-05-06 @ 6:41 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05741528
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2024-02-20
First Post:
2023-02-13
Brief Title:
An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication
Sponsor:
Sumitomo Pharma America Inc
Organization:
Sumitomo Pharma America Inc
Organization Data
Organization:
Sumitomo Pharma America Inc
Class:
INDUSTRY
Study ID:
SEP361-309
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Sumitomo Pharma America Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None